Ibex Medical Analytics Ltd. extended the reach of its artificial intelligence (AI) powered pathology system, adding gastric cancer to existing CE mark approvals in prostate and breast cancer.
In May, Sidekick Health AB revealed an expanded partnership with New York-based Pfizer Inc. for autoimmune-related conditions. Now, it has joined forces with Eli Lilly and Co. to help patients battling breast cancer with its gamified platform. The companies plan to introduce the integrated digital therapeutic starting in July with the roll out beginning in Germany.
Bioinvent International AB is banking an up-front payment of $25 million as part of an option and license agreement with Exelixis Inc., which aims to discover antibodies acting on new immuno-oncology targets. Further financial details were not disclosed, but the alliance entails the discovery of three novel targets and their associated antibodies, identified through Bioinvent’s F.I.R.S.T. screening platform and its n-Coder antibody library.
Profoundbio Inc. closed a $70 million series A financing round that will see it advance its two lead antibody-drug conjugate (ADC) programs to the clinic. The Suzhou, China, and Woodinville, Wash.-based company has raised a total of more than $138 million in the past two years.
Daiichi Sankyo Co. Ltd.’s quizartinib met the primary endpoint of overall survival in the pivotal phase III Quantum-First study, which tested the addition of quizartinib to chemotherapy vs. chemotherapy alone for adults with newly diagnosed FLT3-ITD-positive acute myeloid leukemia (AML).
Everest Medicines Ltd. has picked up its first marketing approval in China for Trodelvy (sacituzumab govitecan), a medicine licensed from Gilead Sciences Inc. It was approved to treat adults with unresectable locally advanced or metastatic triple-negative breast cancer who have received two or more prior systemic therapies, at least one of them for metastatic disease.
RSS
